• Radioisotope journal
• /
• v.6 no.1
• /
• pp.12-17
• /
• 1991

• Journal of Radiation Protection and Research
• /
• v.32 no.3
• /
• pp.117-122
• /
• 2007

The hydrodynamic behaviors of the clarifier with an interior baffle in a wastewater treatment plant was investigated by using a radiotracer $^{99m}Tc$(30 40 mCi) to verify the results of CFD(computational fluid dynamics) modelling in the previous study. The clarifier model was manufactured with consideration to the hydraulic similarity(1/21) of a real plant($L{\times}W{\times}H:2.6{\times}0.4{\times}0.2m$). By installation of an interior baffle to the clarifier, the strong density current at the bottom of the clarifier decreased substantially and increased the area of sludge settling zone, which were visualized successfully from the radiotracer experiment. Also the portion of short circuit stream changed from 48 % to 32 % and the mean residence time of sludge decreased from 940 sec to 810 sec, which corresponds to the results of CFD modelling. As a result, it is anticipated that radiotracer technology can be used as an important tool for designing new wastewater treatment plants and verifying their performances after structural modifications.

• The Korean Journal of Nuclear Medicine
• /
• v.38 no.4
• /
• pp.325-329
• /
• 2004

Purpose: Usefulness of mouse liver S9 fraction was evaluated for the measurement of the metabolites in the in vitro metabolism study of $^{18}F$-labeled radiotracers. Materials and Methods: Mouse liver S9 fraction was isolated at au early step in the course of microsome preparation. The in vitro metabolism studies were tarried out by incubating a mixture containing the radiotracer, S9 fraction and NADPH at $37^{\ciirc}C$, and an aliquot of the mixture was analyzed at the indicated time points by radio-TLC. Metabolic defluorination was further confirmed by the incubation with calcium phosphate, a bone mimic. Results: The radiotracer $[^{18}F]1$ underwent metabolic defluorination within 15 min, which was consistent with the results of the in vivo method and the in vitro method using microsome. Radiotracer $[^{18}F]2$ was metabolized to three metabolites including $4-[^{18}F]fluorobenzoic$ acid within 60 min. It is likely that the one of these metabolites at the origin of radio-TLC was identical with the one that obtained from the in vivo and in vitro (microsome) method. Compared with the in vitro method using microsome, the method using S9 fraction gave a similar pattern of the metabolites but with a different ratio, which can be explained by the presence of cytosol in the S9 fraction. Conclusion: These results suggest that the findings of the in vitro metabolism studies using S9 fraction can reflect the in vivo metabolism of novel radiotracers in the liver. Moreover, this method can be used as a tool to determine metabolic defluorination along with calcium phosphate absorption method.

• Proceedings of the Korean Nuclear Society Conference
• /
• 1999.05a
• /
• pp.396-396
• /
• 1999

• The Korean Journal of Nuclear Medicine
• /
• v.38 no.6
• /
• pp.532-539
• /
• 2004

Purpose: There has been a renewal of interest in Macrophage migration inhibitory factor (MIF), especially correlation in pathogenesis of sepsis by many infectious diseases and in regulation of host inflammatory and immune response. We developed immunoradiometric assay (IRMA) to determine serum human MIF concentration. Materials and Methods: The IRMA system utilizes solid phase bound monoclonal anti-recombinant human MIF (rhMIF) antibody as a capture antibody, biotinylated polyclonal anti-rhMIF antibody as a detector antibody. We applied with rhMIF that concentration of standard solutions increased from 0 ng/ml to 100 ng/ml. We used $^{125}I$-streptavidin (SA) as radiotracer to determination of rhMIF concentration. Streptavidin was labeled with $^{125}I$ by Chloramine-T method and $^{125}I$-SA was purified by ultracentrifugation. $^{125}I$-SA stability was evaluated by ITLC analysis at $4^{\circ}C$ and room temperatures until 60days. To validate IRMA system for MIF, we experimented intra-assay and inter-assay coefficients of variation, recovery test and dilution test. Results: Radiolabeling yield of $^{125}I$-SA was 87% and purified $^{125}I$-SA retained above 99% radiochemical purity. $^{125}I$-SA showed above 93% stability in $4^{\circ}C$ until 60days that it is good for immunoradiometric assay as radiotracer. Plotted standard dose response curve showed that increased concentration of rhMIF linearly correlated (R2=0.99) with bound radioactivity of $^{125}I$-SA. The highest intra- and inter-assay coefficients of variation were 5.5% and 7.6%, respectively. The average of recovery of MIF in samples was 102%. In dilution test, linear response curves were obtained (R2=0.97). Conclusion: Radioimmunoassay using $^{125}I$-SA as radiotracer thought to be useful for the determination of serum MIF concentration, and further, its data will be used to evaluate the correlation between clinical significance and serum MIF concentration in patients with various inflammatory diseases.

• The Journal of the Korea Contents Association
• /
• v.9 no.11
• /
• pp.262-270
• /
• 2009

$^{18}F$-mefway has been developed as radioligand for serotonin receptor 5-$HT_{1A}$. The object of this study was to obtain the mefway precursor with the higher yield than previous method and to identify whether $^{18}F$-mefway can bind to 5-$HT_{1A}$ or not. from microPET imaging of small animal brain. Precursor was prepared by a modification of the reported procedure then [$^{18}F$] labeling was performed by adding $^{18}F$ ion at $130^{\circ}C$ in the hot cell for 30min. After purification of reaction mixture using alumina Sep-pak and HPLC, microPET images of small animal brain were determined. The chemical yield of precursor was increased from 9% to 34% using oxalyl chloride and LAH/diethylether. We synthesized a precursor which was successfully labeled with no-carrier-added $^{18}F$-by new synthetic route. This research suggest that $^{18}F$-mefway will be used a radiopharmaceutical for evaluation of central nerve system disorder as imaging a gent for 5-$HT_{1A}$ receptor.

• The Korean Journal of Nuclear Medicine
• /
• v.37 no.1
• /
• pp.53-62
• /
• 2003

After the development of two major techniques - SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) to image the human subjects in a three-dimensional direction in the 1980s, many radiotracers have been used for functional neuroimaging. Still it would be very important study to develop selective radiotracers for functional neuroimaging. New radiotracers will help to expand the knowledge of neurotransmitter systems and of the genetic contribution to receptor or transporter availability. Neurotransmitter depletion-restoration studies, the distribution of brain functions and their modulation by neurotransmitter system aid in better understanding and limiting the side effects of drugs used as well as newly developed. In audition, these radiotracers will be thus very useful to gain a better understanding in biochemical and pharmacological interactions in living human. This review mentions the introduction of radioligands for the functional neuroimaging. Although significant progress has been achieved in the development of new PET and SPECT ligands for in vivo imaging of those receptors and transporters, there are continuous needs of new diagnostic radioligands.

• The Korean Journal of Nuclear Medicine
• /
• v.31 no.4
• /
• pp.421-426
• /
• 1997

We evaluated the in vivo kinetics, distribution, and pharmacology of N-(4-[$^{18}F$]fluoromethylbenzyl)spiperone ([$^{18}F$]FMBS), a newly developed derivative of spiperone, as a potentially more selective radiotracer for the dopamine (DA) $D_2$ receptors. Mice received 1.9-3.7 MBq (1.8-3.6 nmol/kg) of [$^{18}F$]FMBS by tail vein injection. The time course and regional distribution of the tracer in brain were assessed. Blocking studies were carried out by intravenously preinjecting DA $D_2$ receptor blockers (spiperone, butaclamol) as well as drugs with high affinity for DA $D_1$ (SCH 23390), DA transporter (GBR 12909), and serotonin $S_2$ ($5-HT_2$) (ketanserin) sites. After injection of the tracer, the radioactivity in striatum increased steadily over time, resulting in a striatal-to-cerebellar ratio of 4.8 at 120 min postinjection. By contrast, the radioactivity in cerebellum, frontal cortex, and remaining cortex washed out rapidly. Preinjection of unlabeled FMBS (1 mg/kg) and spiperone (1 mg/kg) reduced [$^{18}F$]FMBS striatal-to-cerebellar ratio by 41% and 80%, respectively. (+)-Butaclamol (1 mg/kg) blocked 80% of the striatal [$^{18}F$]FMBS binding, while (-)-butaclamol (1 mg/kg) did not. Preinjection of SCH 23390 (1 mg/kg) and GBR 12909 (5 mg/kg) had no significant effect on [$^{18}F$]FMBS binding. Ketanserin (1 mg/kg), a ligand for the $5-HT_2$ receptors, did not cause significant inhibition either in striatum, in frontal cortex, or the remaining cortex. The results demonstrate that [$^{18}F$]FMBS labels DA $D_2$ receptors selectively in vivo in the mouse brain. It may hold promise as a selective radiotracer for studying DA $D_2$ receptors in vivo by PET.

• Nuclear Medicine and Molecular Imaging
• /
• v.42 no.3
• /
• pp.185-191
• /
• 2008

While indirect targeting strategies using reporter-genes are taking center stage in current molecular imaging research, another vital strategy has long involved direct imaging of specific receptors using radiolabeled ligands. Recently, there is renewal of immense interest in this area with particular attention to the epidermal growth factor receptor (EGFR), a transmembrane glycoprotein critically involved in the regulation of many cellular functions and malignancies. Recently, two novel classes of EGFR-targeting anticancer drugs have entered clinical trials with great expectations. These are monoclonal antibodies such as cetuximab that target the extracellular domain, and small molecule tyrosine kinase inhibitors such as gefitinib (lressa) and erlotinib (Tarceva) that target the catalytic domain of the receptor. However, early results have showed disappointing survival benefits, disclosing a major challenge for this therapeutic strategy; namely, the need to identify tumors that are most likely to respond to the agents. To address this important clinical issue, several noninvasive imaging techniques are under investigation including radiolabeled probes based on small molecule tyrosine kinase inhibitors, anti-EGFR antibodies, and EGF peptides. This review describes the current status, limitations, and future prospects in the development of radiotracer methods for EGFR imaging.

• Journal of Radiation Industry
• /
• v.9 no.3
• /
• pp.131-135
• /
• 2015

The flow characteristics of fluid were measured using radioactive tracer in pilot scale digester with tray motion mixer. In consideration of the detection volume of the detector and the size of the digester, 20 detectors were installed in the digester. The radioactive tracer eluted 8 mCi of $^{68}Ga$ from $^{68}Ge/^{68}Ga$ generator was injected into the digester bottom. After radiotracer injection, the flow pattern was measured on the basis of the initial movement of the tracer until its diffusion completely. Most of tracer moved to the wall along the bottom of the digester, and then rose along the wall. The other tracer moved up along the mixer, and then moved to the wall direction along the surface.